JP2017516870A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516870A5
JP2017516870A5 JP2017516633A JP2017516633A JP2017516870A5 JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5 JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
subject
antigen
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516870A (ja
JP6686007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2015/050651 external-priority patent/WO2015187087A2/en
Publication of JP2017516870A publication Critical patent/JP2017516870A/ja
Publication of JP2017516870A5 publication Critical patent/JP2017516870A5/ja
Application granted granted Critical
Publication of JP6686007B2 publication Critical patent/JP6686007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516633A 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用 Active JP6686007B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450678-6 2014-06-04
SE1450678 2014-06-04
SE1451315 2014-11-04
SE1451315-4 2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en) 2014-06-04 2015-06-04 Novel combinations for antigen based therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020066176A Division JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Publications (3)

Publication Number Publication Date
JP2017516870A JP2017516870A (ja) 2017-06-22
JP2017516870A5 true JP2017516870A5 (enExample) 2018-06-28
JP6686007B2 JP6686007B2 (ja) 2020-04-22

Family

ID=54767532

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017516633A Active JP6686007B2 (ja) 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Country Status (20)

Country Link
US (3) US20170196949A1 (enExample)
EP (2) EP3151853B1 (enExample)
JP (2) JP6686007B2 (enExample)
CN (2) CN114504639A (enExample)
AU (3) AU2015268960B2 (enExample)
CA (2) CA2950893C (enExample)
CY (1) CY1123160T1 (enExample)
DK (1) DK3151853T3 (enExample)
ES (1) ES2807787T3 (enExample)
HU (1) HUE051151T2 (enExample)
IL (3) IL300130B2 (enExample)
LT (1) LT3151853T (enExample)
PL (1) PL3151853T3 (enExample)
PT (1) PT3151853T (enExample)
RS (1) RS60581B1 (enExample)
RU (1) RU2702632C2 (enExample)
SI (1) SI3151853T1 (enExample)
SM (1) SMT202000384T1 (enExample)
WO (1) WO2015187087A2 (enExample)
ZA (1) ZA202204777B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP4300102A3 (en) 2017-09-08 2024-01-24 Diamyd Medical AB Improved immunotherapy
DK3678692T3 (da) * 2017-09-08 2022-01-03 Diamyd Medical Ab Genotypestratificering ved behandling og forebyggelse af diabetes
WO2019151939A1 (en) * 2018-02-05 2019-08-08 Diamyd Medical Ab Novel composition and use thereof
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
US10500217B2 (en) 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
CA3136360A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
EP4243769A2 (en) * 2020-11-16 2023-09-20 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled injection devices without fatty acid particles
US20240245762A1 (en) * 2021-01-13 2024-07-25 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
EP4373517A1 (en) * 2021-06-17 2024-05-29 Phaim Pharma Ltd Individualized cell therapy using patient-derived antigen-specific regulatory t cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
EP0869815A1 (en) * 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
NZ567150A (en) * 2005-10-05 2011-12-22 Bayhill Therapeutics Inc Compositions and methods for treatment of autoimmune disease
CN101646781B (zh) * 2006-12-29 2016-06-22 科罗拉多大学董事会 自身免疫病的诊断和治疗靶标及其用途
EP2131856B1 (en) * 2007-03-07 2014-09-17 UTI Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
CN103768580A (zh) * 2007-12-19 2014-05-07 托勒兰泽亚股份公司 治疗自身免疫和过敏性疾病的组合物及方法
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2017516870A5 (enExample)
RU2016150656A (ru) Новые комбинации для антигенной терапии
Neurath et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question
Xie et al. Enteroendocrine hormone secretion and metabolic control: importance of the region of the gut stimulation
Von Herrath et al. Type 1 diabetes as a relapsing–remitting disease?
Li et al. L-Theanine improves immunity by altering TH2/TH1 cytokine balance, brain neurotransmitters, and expression of phospholipase C in rat hearts
Ni et al. Advances in immunotherapy of type I diabetes
Marcinkowska et al. The use of 1α, 25-dihydroxyvitamin D3 as an anticancer agent
Gallagher et al. Making progress: preserving beta cells in type 1 diabetes
Cook et al. Prospects of a type 1 diabetes vaccine
Colceriu-Șimon et al. The Effects of Non-Steroidal Anti-Inflammatory Drugs Used for Orthodontic Pain Management on Tooth Movement: A Comprehensive Review of the Literature
Juedes et al. Regulatory T‐cells in type 1 diabetes
Korkmaz et al. Liraglutide-related cholelithiasis
Davalli et al. Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures
HRP20201030T1 (hr) Dekarboksilaza glutaminske kiseline (gad) za uporabu za liječenje autoimune bolesti
Rajasalu et al. Experimental Autoimmune Diabetes: A New Tool to Study Mechanisms and Consequences of Insulin‐Specific Autoimmunity
Fabbrini et al. Soluble and controlled-release preparations of levodopa: do we really need them?
JP2928608B2 (ja) インスリン依存型糖尿病予防または治療剤
Shao et al. Treatment of disease through oral tolerance
Page et al. Adaptive Responses in Severe Acute Malnutrition: Endocrinology, Metabolomics, Mortality, and Growth
RU2824503C2 (ru) Новые комбинации для антигенной терапии
Van et al. All-trans retinoic acids inhibits type 1 diabetes by Treg-dependent suppression of IFN-γ-producing-T-cells without affecting Th17 cells
Sonino et al. Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly